Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Stockholders Equity of $1.13 billion for the year ending 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +9.3% in Stockholders Equity from 2024 to 2025.
- This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$141.39 million | Q2 2020: -$159.44 million | Q3 2020: -$182.08 million | Q1 2021: -$233.03 million | Q2 2021: $642.71 million | Q3 2021: $599.03 million | Q1 2022: $493.57 million | Q2 2022: $437.58 million | Q3 2022: $388.03 million | Q1 2023: $430.18 million | Q2 2023: $468.96 million | Q3 2023: $437.97 million | Q1 2024: $401.15 million | Q2 2024: $584.45 million | Q3 2024: $524.56 million | Q1 2025: $933.95 million | Q2 2025: $919.15 million | Q3 2025: $1.05 billion.
- Over the full 8 years of available data (2018 to 2025), RECURSION PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 1,871.2%.
- Historical annual values: Fiscal year 2025: $1.13 billion | Fiscal year 2024: $1.03 billion | Fiscal year 2023: $463.44 million | Fiscal year 2022: $485.81 million | Fiscal year 2021: $542.94 million | Fiscal year 2020: -$206.29 million | Fiscal year 2019: -$124.27 million | Fiscal year 2018: -$63.85 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: